Prospect of Newcastle disease virus in clinical neurological tumour diseases

IF 4.2 2区生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

Biochimica et biophysica acta. Molecular basis of disease Pub Date : 2025-08-21 DOI:10.1016/j.bbadis.2025.168025

Yuxin Chen , Zecheng Yu , Huazhong Ying , Fangwei Dai , Wei Han

{"title":"Prospect of Newcastle disease virus in clinical neurological tumour diseases","authors":"Yuxin Chen , Zecheng Yu , Huazhong Ying , Fangwei Dai , Wei Han","doi":"10.1016/j.bbadis.2025.168025","DOIUrl":null,"url":null,"abstract":"<div><div>Newcastle disease virus (NDV) can activate an anti-tumour immune response, and the virus has tumour-lysing properties and can induce apoptosis in tumour cells. NDV is used as a vector in oncolytic virus therapy, which has the unique advantage of tumour-specific inflammation activation, and drug resistance avoidance, resulting in the killing of tumour cells and induction of systemic anti-tumour immunity. NDV uses cancer signalling pathways to transform the immune-desert and microenvironment and immune-rejecting tumours into immunoinflammatory tumours, activating innate and adaptive anti-tumour immune responses to kill tumour cells, and its clinical application is one of the emerging cancer therapies focused on by researchers with good prospects for translational applications. The article reviews the mechanisms of NDV infection and oncolysis, and the clinical applications and safety of tumour oncolysis in nervous system tumours. This may contribute to enhancing further intervention and treatment of neurological tumours with NDV and lay the foundation for the widespread clinical use of NDV as a neoadjuvant therapeutic treatment.</div></div>","PeriodicalId":8821,"journal":{"name":"Biochimica et biophysica acta. Molecular basis of disease","volume":"1871 8","pages":"Article 168025"},"PeriodicalIF":4.2000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochimica et biophysica acta. Molecular basis of disease","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0925443925003734","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Newcastle disease virus (NDV) can activate an anti-tumour immune response, and the virus has tumour-lysing properties and can induce apoptosis in tumour cells. NDV is used as a vector in oncolytic virus therapy, which has the unique advantage of tumour-specific inflammation activation, and drug resistance avoidance, resulting in the killing of tumour cells and induction of systemic anti-tumour immunity. NDV uses cancer signalling pathways to transform the immune-desert and microenvironment and immune-rejecting tumours into immunoinflammatory tumours, activating innate and adaptive anti-tumour immune responses to kill tumour cells, and its clinical application is one of the emerging cancer therapies focused on by researchers with good prospects for translational applications. The article reviews the mechanisms of NDV infection and oncolysis, and the clinical applications and safety of tumour oncolysis in nervous system tumours. This may contribute to enhancing further intervention and treatment of neurological tumours with NDV and lay the foundation for the widespread clinical use of NDV as a neoadjuvant therapeutic treatment.

查看原文本刊更多论文

新城疫病毒在临床神经肿瘤疾病中的应用前景

新城疫病毒（NDV）可激活抗肿瘤免疫反应，具有溶瘤特性，可诱导肿瘤细胞凋亡。NDV作为溶瘤病毒治疗的载体，具有肿瘤特异性炎症激活和避免耐药的独特优势，可杀死肿瘤细胞并诱导全身抗肿瘤免疫。NDV通过肿瘤信号通路将免疫荒漠、微环境、免疫排斥肿瘤转化为免疫炎性肿瘤，激活先天和适应性抗肿瘤免疫应答，杀伤肿瘤细胞，其临床应用是目前研究人员关注的新兴肿瘤治疗方法之一，具有良好的转化应用前景。本文综述了NDV感染和溶瘤的机制，以及肿瘤溶瘤在神经系统肿瘤中的临床应用和安全性。这可能有助于加强NDV对神经系统肿瘤的进一步干预和治疗，并为NDV作为新辅助治疗的广泛临床应用奠定基础。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biochimica et biophysica acta. Molecular basis of disease 生物-生化与分子生物学

CiteScore

12.30

自引率

0.00%

发文量

218

审稿时长

32 days

期刊介绍： BBA Molecular Basis of Disease addresses the biochemistry and molecular genetics of disease processes and models of human disease. This journal covers aspects of aging, cancer, metabolic-, neurological-, and immunological-based disease. Manuscripts focused on using animal models to elucidate biochemical and mechanistic insight in each of these conditions, are particularly encouraged. Manuscripts should emphasize the underlying mechanisms of disease pathways and provide novel contributions to the understanding and/or treatment of these disorders. Highly descriptive and method development submissions may be declined without full review. The submission of uninvited reviews to BBA - Molecular Basis of Disease is strongly discouraged, and any such uninvited review should be accompanied by a coverletter outlining the compelling reasons why the review should be considered.